These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 21917518)

  • 81. PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
    Loibl S; von Minckwitz G; Schneeweiss A; Paepke S; Lehmann A; Rezai M; Zahm DM; Sinn P; Khandan F; Eidtmann H; Dohnal K; Heinrichs C; Huober J; Pfitzner B; Fasching PA; Andre F; Lindner JL; Sotiriou C; Dykgers A; Guo S; Gade S; Nekljudova V; Loi S; Untch M; Denkert C
    J Clin Oncol; 2014 Oct; 32(29):3212-20. PubMed ID: 25199759
    [TBL] [Abstract][Full Text] [Related]  

  • 82. TOP2A gene copy number change in breast cancer.
    Engstrøm MJ; Ytterhus B; Vatten LJ; Opdahl S; Bofin AM
    J Clin Pathol; 2014 May; 67(5):420-5. PubMed ID: 24403186
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Topoisomerase II α Gene alteration in Triple Negative Breast Cancer and Its Predictive Role for Anthracycline-Based Chemotherapy (Egyptian NCI Patients).
    Eltohamy MI; Badawy OM; El kinaai N; Loay I; Nassar HR; Allam RM; Sakr MA
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3581-3589. PubMed ID: 30583686
    [TBL] [Abstract][Full Text] [Related]  

  • 84. HER-2, TOP2A and chromosome 17 alterations in breast cancer.
    Beser AR; Tuzlali S; Guzey D; Dolek Guler S; Hacihanefioglu S; Dalay N
    Pathol Oncol Res; 2007; 13(3):180-5. PubMed ID: 17922046
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications.
    Personeni N; Baretti M; Bozzarelli S; Spaggiari P; Rubino L; Tronconi MC; Fumagalli Romario U; Rosati R; Giordano L; Roncalli M; Santoro A; Rimassa L
    Gastric Cancer; 2017 May; 20(3):428-437. PubMed ID: 27530622
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification.
    Betof AS; Rabbani ZN; Hardee ME; Kim SJ; Broadwater G; Bentley RC; Snyder SA; Vujaskovic Z; Oosterwijk E; Harris LN; Horton JK; Dewhirst MW; Blackwell KL
    Br J Cancer; 2012 Feb; 106(5):916-22. PubMed ID: 22333602
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Time to initiation of adjuvant chemotherapy in patients with rapidly proliferating early breast cancer.
    Farolfi A; Scarpi E; Rocca A; Mangia A; Biglia N; Gianni L; Tienghi A; Valerio MR; Gasparini G; Amaducci L; Faedi M; Baldini E; Rubagotti A; Maltoni R; Paradiso A; Amadori D
    Eur J Cancer; 2015 Sep; 51(14):1874-81. PubMed ID: 26206258
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.
    Kotoula V; Bobos M; Alexopoulou Z; Papadimitriou C; Papadopoulou K; Charalambous E; Tsolaki E; Xepapadakis G; Nicolaou I; Papaspirou I; Aravantinos G; Christodoulou C; Efstratiou I; Gogas H; Fountzilas G
    PLoS One; 2014; 9(8):e103707. PubMed ID: 25098819
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer.
    Buzdar AU
    J Clin Oncol; 2006 Jun; 24(16):2409-11. PubMed ID: 16682721
    [No Abstract]   [Full Text] [Related]  

  • 90. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.
    Arriola E; Marchio C; Tan DS; Drury SC; Lambros MB; Natrajan R; Rodriguez-Pinilla SM; Mackay A; Tamber N; Fenwick K; Jones C; Dowsett M; Ashworth A; Reis-Filho JS
    Lab Invest; 2008 May; 88(5):491-503. PubMed ID: 18332872
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Does topoisomerase II-alpha gene amplification provide useful information for treatment selection in patients with breast carcinoma?
    Simon R
    J Clin Oncol; 2011 Jul; 29(21):2941; author reply 2941-4. PubMed ID: 21670460
    [No Abstract]   [Full Text] [Related]  

  • 92. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.
    ; Peto R; Davies C; Godwin J; Gray R; Pan HC; Clarke M; Cutter D; Darby S; McGale P; Taylor C; Wang YC; Bergh J; Di Leo A; Albain K; Swain S; Piccart M; Pritchard K
    Lancet; 2012 Feb; 379(9814):432-44. PubMed ID: 22152853
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Anthracycline Use for Early Stage Breast Cancer in the Modern Era: a Review.
    Jasra S; Anampa J
    Curr Treat Options Oncol; 2018 May; 19(6):30. PubMed ID: 29752560
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer.
    Järvinen TA; Liu ET
    Curr Cancer Drug Targets; 2006 Nov; 6(7):579-602. PubMed ID: 17100565
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Aberrations of ERBB2 and TOP2A genes in breast cancer.
    Nielsen KV; Müller S; Møller S; Schønau A; Balslev E; Knoop AS; Ejlertsen B
    Mol Oncol; 2010 Apr; 4(2):161-8. PubMed ID: 19945923
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes.
    Olsen KE; Knudsen H; Rasmussen BB; Balslev E; Knoop A; Ejlertsen B; Nielsen KV; Schönau A; Overgaard J;
    Acta Oncol; 2004; 43(1):35-42. PubMed ID: 15068318
    [TBL] [Abstract][Full Text] [Related]  

  • 97. A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification.
    Tarpgaard LS; Qvortrup C; Nygård SB; Nielsen SL; Andersen DR; Jensen NF; Stenvang J; Detlefsen S; Brünner N; Pfeiffer P
    BMC Cancer; 2016 Feb; 16():91. PubMed ID: 26867764
    [TBL] [Abstract][Full Text] [Related]  

  • 98. In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer.
    Spears M; Taylor KJ; Munro AF; Cunningham CA; Mallon EA; Twelves CJ; Cameron DA; Thomas J; Bartlett JM
    Breast Cancer Res Treat; 2012 Apr; 132(2):463-70. PubMed ID: 21638049
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
    Fujii T; Le Du F; Xiao L; Kogawa T; Barcenas CH; Alvarez RH; Valero V; Shen Y; Ueno NT
    JAMA Oncol; 2015 Dec; 1(9):1311-8. PubMed ID: 26402167
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
    Oakman C; Moretti E; Sotiriou C; Viale G; Di Leo A
    J Natl Cancer Inst; 2009 Dec; 101(24):1735-6; author reply 1736-7. PubMed ID: 19893008
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.